Clinical Study

A Phase 2 Randomized Study Of Efatutazone, An Oral Ppar Agonist, In Combination With Paclitaxel Versus Paclitaxel In Patients With Advanced Anaplastic Thyroid Cancer

Posted Date: Oct 8, 2014

  • Investigator: Nooshin Hashemi Sadraei
  • Co-Investigator: Null Null
  • Specialties: Hematology/Oncology, Oncology, Cancer, Head & Neck Cancer
  • Type of Study: Drug

The purpose of this study is to compare any good and bad effects of using efatutazone along with the usual chemotherapy to using the usual chemotherapy alone.

Criteria:

To Be Eligible For This Study, Patients Must Have Anaplastic Thyroid Cancer Which Cannot Be Removed With Surgery Or Has Spread To Other Areas Of The Body.

Keywords:

Advanced Anaplastic Thyroid Cancer, Thyroid Cancer, A091305, Cancer, Head & Neck, 2014-5243

For More Information:

Uc Cancer Institute
513-584-7698
kastla@uc.edu

  • Search Clinical Studies

  • Research in the News

    Targeted Treatment Could Prevent Spread of Pancreatic Cancer, Heart Damage

    Researchers at the UC College of Medicine have shown that a new targetedtreatment could benefit patients with certain pancreatic tumors.